These consensus recommendations offer guidance on optimal therapeutic strategies for HR+/HER2- metastatic breast cancer within the Canadian landscape, including integration of precision oncology and targeted therapies, optimal sequencing of therapies, and the importance of balancing the benefits of treatments with patient quality of life and preferences. Here, ERBB2 is linked to breast carcinoma.